Aging is notoriously associated with a decline in immune function, leading to increased susceptibility to infectious diseases and diminished vaccine efficacy among older adults. Zhang’s research aims to decode the molecular underpinnings of this deterioration, focusing on the epigenetic regulation of T cell aging, specifically the role of a protein called HELIOS in helper T cells—a critical subset of immune cells orchestrating the body’s antibody production. Her laboratory hypothesizes that age-related loss of HELIOS disrupts the functional crosstalk between helper T cells and B cells, weakening humoral immunity.

Helper T cells, often described as the immune system’s “coaches,” are essential in guiding B cells to produce high-affinity antibodies that neutralize pathogens. Zhang’s work has revealed that the decline of HELIOS in these cells is central to the loss of this guiding function. This protein acts as an epigenetic regulator, influencing gene expression patterns that determine T cell differentiation and function. The gradual depletion of HELIOS with age results in compromised T follicular helper (TFH) cell activity, thereby impairing the body’s ability to mount robust antibody responses.

The innovative aspect of Zhang’s project lies in investigating whether restoring HELIOS expression in aged T cells can rejuvenate their function. By deploying cutting-edge molecular biology techniques and epigenomic profiling, her lab is exploring the possibility of reprogramming aged immune cells to regain youthful functionality. If successful, this approach could revolutionize vaccine development by creating strategies that bolster immune responsiveness, especially in populations that typically exhibit poor vaccine outcomes.

One of the technical focal points of Zhang’s research is the mechanistic understanding of HELIOS as a transcription factor modulating chromatin accessibility and gene transcription in aging T cells. Utilizing single-cell RNA sequencing and chromatin immunoprecipitation assays, her team aims to map the epigenetic landscape changes accompanying T cell senescence. These methodologies offer unprecedented resolution into how aging remodels immune cell function at a molecular scale.

Moreover, by delineating the pathways governing HELIOS expression and its regulatory network, Zhang’s research could identify novel molecular targets for immunotherapeutic interventions. The potential to develop small molecules or biologics that mimic or enhance HELIOS function may open new horizons for therapies designed to reinvigorate the aged immune system. This could lead to reduced morbidity and mortality from infections such as influenza, pneumonia, and shingles among the elderly.

Zhang’s research also underscores a paradigm shift in the conceptualization of aging immunity—not as irrevocably broken but as malleable and reprogrammable. This perspective fuels a proactive approach to medicine, focusing on restoring immune vigor rather than merely managing age-associated diseases. By leveraging molecular reprogramming, therapies may enable older adults to maintain disease resistance akin to younger individuals, substantially improving healthspan.

The potential societal impact of these findings is vast. Strengthening immune defenses in the aging population can dramatically reduce hospitalization rates and healthcare costs associated with infectious diseases in seniors. Enhancing vaccine efficacy through molecular adjuncts targeting HELIOS pathways could redefine public health strategies, particularly in the wake of pandemics where vulnerable groups suffer disproportionate mortality.

Beyond its therapeutic implications, Zhang’s work contributes to the fundamental understanding of immunosenescence—the gradual deterioration of the immune system with age—and the epigenetic factors steering it. Such knowledge enriches the broader scientific discourse on aging biology and promotes the integration of immunology and epigenetics to form more comprehensive models of age-related decline.

Zhang’s academic pedigree, including a doctorate in biochemistry and molecular biology from UCLA and postdoctoral training at renowned institutions such as The Scripps Research Institute and Stanford University, underpins her expertise in this interdisciplinary field. Since joining UC Riverside in 2023, she has committed to mentoring the next generation of scientists navigating the converging realms of aging and immune research.

The 2025 Junior Faculty Grant from AFAR not only supports Zhang’s research financially but also signifies recognition from a leading organization dedicated to pioneering biomedical research on aging. AFAR’s mission to catalyze scientific advances and translate them into practical interventions aligns seamlessly with Zhang’s visionary goals.

In sum, Huimin Zhang’s trailblazing research into the role of HELIOS in T cell aging opens a promising frontier in gerontology and immunology. By decoding and potentially reversing the epigenetic alterations that undermine immune function, her work aspires to transform the science of aging, making it a cornerstone in the development of advanced therapies that enhance longevity and quality of life. The scientific community eagerly anticipates the unfolding breakthroughs from her lab, which could redefine how we perceive and treat the aging immune system.

Subject of Research: Epigenetic regulation of T cell aging; role of HELIOS in immune function and T follicular helper cell differentiation
Article Title: Exploring HELIOS: Reprogramming Immune Aging to Enhance Vaccine Efficacy in the Elderly
News Publication Date: 2024
Web References:

• American Federation for Aging Research (AFAR): https://www.afar.org/
• UC Riverside Molecular, Cell and Systems Biology Profile: https://mcsb.ucr.edu/
• Huimin Zhang Lab: https://zlabimmunol.bio/
  Image Credits: Zhang lab, UC Riverside
  Keywords: HELIOS, T cell aging, epigenetic regulation, immunosenescence, helper T cells, T follicular helper cells, aging immunity, vaccine enhancement, B cell function, molecular reprogramming, immune rejuvenation, AFAR Junior Faculty Grant

Atherosclerosis remains a leading cause of morbidity and mortality worldwide, largely driven by the accumulation of lipid-laden macrophages, known as foam cells, within arterial walls. These transformed macrophages contribute to plaque formation, instability, and eventual cardiovascular events. Central to this pathological process is the reprogramming of macrophage metabolism and gene expression, which has spurred intensive research efforts aimed at identifying molecular interventions capable of restoring cellular homeostasis and attenuating inflammatory damage.

The crux of the new study lies in the targeted delivery of microRNA-10a (miR-10a) encapsulated in liposomes, which specifically modulate the metabolic machinery and epigenetic regulators of macrophages implicated in atherosclerotic progression. MicroRNAs, small non-coding RNA molecules, play pivotal roles in post-transcriptional gene silencing and have emerged as potent modulators of immune cell phenotype. By harnessing miR-10a’s regulatory potential, the researchers sought to shift the metabolic state of macrophages from a pro-inflammatory to a reparative, anti-atherogenic profile.

Mitochondrial metabolism is increasingly recognized as a central node in immune cell programming, influencing not only energy production but also the generation of signaling metabolites that dictate epigenetic landscapes. In the context of macrophages, a shift towards oxidative phosphorylation and enhanced mitochondrial function correlates with resolution of inflammation, whereas glycolytic reprogramming promotes sustained pro-inflammatory states. The study demonstrates that miR-10a liposomes restore mitochondrial integrity and bioenergetic capacity, leading to marked reductions in inflammatory cytokine expression and foam cell formation.

Crucially, the therapeutic efficacy of miR-10a was linked to its impact on epigenetic regulators, specifically histone-modifying enzymes that control chromatin accessibility and gene transcription patterns. Through downregulation of key histone deacetylases and methyltransferases, miR-10a facilitated the reactivation of genes involved in lipid metabolism and anti-inflammatory responses. This dual action on mitochondrial function and epigenetic control represents a synergistic mechanism that efficiently reprograms macrophages, attenuating the pathogenic cycle that underpins atherosclerosis.

Liposomes served as a highly effective delivery vehicle, overcoming previous barriers related to stability, cellular uptake, and targeted tissue distribution of RNA therapeutics. Their nanoscale size and biocompatibility enabled precise delivery of miR-10a to macrophages within the atherosclerotic plaque microenvironment. Upon administration in murine models of atherosclerosis, miR-10a liposomes significantly reduced plaque burden and improved arterial function, providing compelling in vivo validation of this strategy.

Beyond plaque regression, the treatment also enhanced systemic metabolic profiles, as evident by improved lipid panels and reduced markers of systemic inflammation. This suggests that metabolic reprogramming of macrophages not only impacts local disease processes but may also confer broader cardiovascular benefits. The findings highlight the interconnectedness of immune cell metabolism and systemic homeostasis, expanding the therapeutic potential of miRNA-based interventions.

This study further contributes to the burgeoning field of immunometabolism, where the metabolic state of immune cells is increasingly appreciated as a determinant of their function and fate. By delineating the precise molecular targets of miR-10a and elucidating its epigenetic effects, the research adds valuable insight to the mechanistic underpinnings that govern macrophage plasticity in chronic inflammatory diseases.

The implications for clinical translation are profound. Current atherosclerosis treatments primarily focus on lipid-lowering therapies and symptomatic management, with limited options for directly modulating inflammatory processes at the cellular level. miRNA-based therapeutics, especially those leveraging advanced delivery systems like liposomes, open new frontiers for precision medicine aimed at reprogramming disease-driving immune cells rather than merely suppressing symptoms.

Nevertheless, several challenges remain before this innovative approach can be brought to the clinic. Long-term safety, dosing regimens, and the potential for off-target effects require meticulous evaluation in preclinical and clinical studies. Moreover, the heterogeneity of macrophage populations and their dynamic roles in various stages of atherosclerosis necessitate careful optimization of treatment timing and combinations with existing therapies.

As the study’s first authors underscore, future directions include investigating the combinatorial effects of miR-10a with other metabolic and epigenetic modulators, as well as extending this strategy to other chronic inflammatory and metabolic conditions. The versatility of miRNA therapeutics encoded within liposomes holds promise to revolutionize a spectrum of diseases where immune cell dysfunction is a key driver.

This research epitomizes the power of interdisciplinary collaboration, marrying molecular biology, nanotechnology, immunology, and metabolism to tackle one of the most pressing public health challenges. It underscores the paradigm shift from traditional pharmacology toward sophisticated gene regulatory therapies tailored to the cellular microenvironment and metabolic state.

In summary, the exploitation of miR-10a-loaded liposomes to reprogram mitochondrial metabolism and epigenetic architecture of macrophages marks a transformative advancement in cardiovascular disease therapy. By correcting the root cause of immune dysregulation in atherosclerosis, this approach offers hope for durable, targeted interventions that move beyond symptom control to fundamentally alter disease trajectory.

The exciting convergence of miRNA biology and lipid nanocarrier technology detailed in this study sets the stage for a new era of smart therapeutics that harness endogenous regulatory circuits to restore health. With further refinement and clinical validation, miR-10a liposomal therapy could become a cornerstone in the fight against atherosclerosis, heralding a future where precision epigenetic reprogramming becomes a standard weapon against chronic inflammation.

As researchers continue to decode the complex crosstalk between metabolism and gene expression in immune cells, miRNA-based interventions exemplify the next-generation tools capable of exploiting this nexus. The promise of this innovative treatment lies not only in its therapeutic efficacy but also in its potential to inspire new lines of inquiry into the metabolic-epigenetic interface across multiple disease domains.

Ultimately, this pioneering work reaffirms the shifting paradigm in biomedical research, where the integration of molecular insights and nanomedicine offers unprecedented opportunities to tackle the root causes of disease at a cellular and epigenetic level. The remarkable efficacy of miR-10a liposomes in modulating macrophage function could pave the way for entirely new classes of therapies designed to re-educate the immune system and restore tissue homeostasis.

With cardiovascular disease continuing to impose a staggering global health burden, advances such as these propel us closer to groundbreaking therapies that blend molecular precision with innovative delivery platforms. This study not only showcases the transformative potential of miRNA therapeutics but also exemplifies the future trajectory of personalized medicine aimed at correcting metabolic and epigenetic aberrancies at their source.

Article References:
Fang, F., Wang, E., Yang, H. et al. Reprogramming mitochondrial metabolism and epigenetics of macrophages via miR-10a liposomes for atherosclerosis therapy. Nat Commun 16, 9117 (2025). https://doi.org/10.1038/s41467-025-64201-8

Allergic rhinitis, characterized by chronic nasal inflammation induced by allergens, affects millions globally, significantly diminishing quality of life. Despite extensive research into immunological triggers and environmental factors, the detailed regulatory networks governing immune cell behavior and epithelial barrier function in this disease context remain incompletely understood. This novel investigation shifts focus onto the epitranscriptomic modification landscape—specifically m6A methylation—revealing its profound impact on inflammatory pathways and cellular crosstalk.

At the heart of the discovery is METTL3, a pivotal methyltransferase responsible for catalyzing the addition of N6-methyladenosine (m6A) marks on RNA molecules. These modifications influence RNA metabolism and function, underpinning diverse biological processes. In this latest study, METTL3’s activity on circCDKAL1, a circular RNA species resistant to exonucleases and distinct in its closed-loop structure, emerges as a key regulatory event. By mediating m6A modification, METTL3 alters circCDKAL1’s interaction with RNA-binding proteins, thereby affecting downstream signaling cascades.

Diving deeper into the molecular interplay, the researchers identified a sophisticated axis involving IGF2BP2, JARID2, and HMGB1 proteins. IGF2BP2, an m6A ‘reader’ protein, binds the methylated circCDKAL1, stabilizing it and facilitating the recruitment of epigenetic regulator JARID2. This complex, in turn, influences the expression of HMGB1, a chromatin-associated protein with well-documented roles in inflammation and tissue repair. Through this molecular relay, the study connects epitranscriptomic modifications to the orchestration of macrophage polarization and epithelial barrier dynamics.

Macrophages, the sentinel immune cells of the innate immune system, adapt their phenotype in response to environmental cues, transitioning between the pro-inflammatory M1 and anti-inflammatory M2 states. The study reveals that altered m6A modification of circCDKAL1 skews macrophage polarization favoring the M1 phenotype, which exacerbates inflammatory responses within the nasal mucosa. This shift underscores a mechanistic link between RNA modifications and immune cell functional plasticity, challenging previous understandings and suggesting novel intervention points.

Concurrently, the integrity of the nasal epithelial barrier, the frontline defense against environmental insults, is compromised when this axis is dysregulated. Disruption of this barrier not only facilitates allergen penetration but also perpetuates inflammation, creating a vicious cycle central to allergic rhinitis pathology. By restoring proper m6A modification patterns on circCDKAL1, the researchers could rescue epithelial barrier function, highlighting a potential strategy to fortify mucosal defenses.

The experimental approach encompassed cutting-edge molecular biology techniques, including RNA immunoprecipitation, methylated RNA immunoprecipitation sequencing (MeRIP-seq), and functional assays in macrophage and epithelial cell models. Through these methodologies, the team substantiated the causative role of METTL3-mediated m6A modifications in modulating the downstream IGF2BP2/JARID2/HMGB1 signaling axis, firmly establishing the mechanistic framework connecting epitranscriptomics to cellular phenotype and barrier physiology.

Importantly, this research extends beyond fundamental insights, carrying implications for therapeutic innovation. Targeting the METTL3-circCDKAL1 modification system, or its interaction with IGF2BP2 and downstream effectors, may provide selective means to temper pro-inflammatory macrophage activation and bolster epithelial resilience. This precision could transform allergic rhinitis management, shifting from symptomatic treatment to addressing root molecular dysfunctions.

Additionally, the findings add fresh layers to the expanding narrative on circular RNAs as crucial modulators in immune contexts. Traditionally overlooked as splicing by-products, circRNAs are increasingly recognized as central players in gene expression regulation. This study showcases how their epitranscriptomic landscape governs immune and barrier functions, a paradigm likely relevant in other inflammatory and autoimmune disorders.

The identification of JARID2’s involvement in this regulatory cascade is particularly captivating. As a known modulator of chromatin remodeling and gene expression, JARID2’s interaction within the axis hints at how transcriptional control intertwines with RNA modifications to dictate cell fate and function. This crosstalk exemplifies the intricate connectivity between epigenetic and epitranscriptomic layers in health and disease.

HMGB1’s role, a powerful alarmin and modulator of immune responses, anchors the axis to well-characterized inflammatory signaling networks. Its modulation through this newly discovered pathway suggests opportunities to manipulate known mediators of inflammation via upstream RNA modification targets, offering a multi-tiered approach to intervention.

The study’s authors emphasize the translational potential of their findings, advocating for further in vivo validation and the exploration of small molecules or biologics capable of modulating METTL3 activity or the m6A status of circCDKAL1. Such developments could pave the way for novel therapeutics that dampen allergic inflammation and restore nasal epithelial barrier function with high specificity.

In the broader context of RNA biology and immunology, this research exemplifies how advanced epitranscriptomic profiling can decode complex cellular communications governing disease states. As our toolkit for detecting and manipulating RNA modifications expands, so too will our capacity to develop next-generation immunomodulatory therapies.

Given the intricate interplay between environmental allergens, immune cell behavior, and epithelial architecture in allergic rhinitis, uncovering this epitranscriptomic axis provides a much-needed piece to the puzzle. It opens avenues not only for therapeutic innovation but also for biomarker development, enabling better diagnosis and disease monitoring based on RNA modification patterns.

This landmark contribution establishes a new frontier in allergy research, encouraging multidisciplinary approaches integrating molecular epigenetics, RNA biology, and immunology. The METTL3-circCDKAL1-IGF2BP2/JARID2/HMGB1 axis may soon become a cornerstone target for managing allergic rhinitis and potentially other mucosal inflammatory diseases.

As the field progresses, future studies might explore how environmental factors influence METTL3 activity and circCDKAL1 methylation, illuminating lifestyle or exposure-related modulation of disease severity. Moreover, the role of this pathway in other immune cell subsets and epithelial tissues will undoubtedly be an exciting area of investigation.

In sum, this study shines a spotlight on the transformative power of epitranscriptomic regulation in immune homeostasis and barrier function, reshaping our understanding of allergic rhinitis pathogenesis. It offers hope that by harnessing these molecular insights, clinicians may soon wield more effective and finely tuned tools against this ubiquitous and often underestimated condition.

Subject of Research: Epitranscriptomic regulation of macrophage polarization and nasal epithelial barrier function in allergic rhinitis.

Article Title: METTL3-mediated m6A modification of circCDKAL1 regulates macrophage M1 polarization and nasal epithelial cell barrier function in allergic rhinitis through IGF2BP2/JARID2/HMGB1 axis.

Article References:
Zhan, J., Luo, D., Fu, Y. et al. METTL3-mediated m6A modification of circCDKAL1 regulates macrophage M1 polarization and nasal epithelial cell barrier function in allergic rhinitis through IGF2BP2/JARID2/HMGB1 axis. Cell Death Discov. 11, 417 (2025). https://doi.org/10.1038/s41420-025-02710-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02710-7